As per the terms of the agreement, Synageva is eligible to receive an upfront payment of $3m from Mitsubishi Tanabe.
Additionally, Mitsubishi Tanabe will contribute additional research funds.
Synageva president and CEO Sanj Patel said they look forward to a productive partnership with Mitsubishi Tanabe Pharma that should result in a new treatment for a devastating condition.